Charles H. Hood Foundation | Aldatu Biosciences
By identifying innovative pediatric advancements and providing funding in the critical phases of development, we are able to expedite high-impact breakthroughs that improve the health and lives of millions.
16773
portfolio_page-template-default,single,single-portfolio_page,postid-16773,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-10.0,wpb-js-composer js-comp-ver-4.12,vc_responsive

Program Related Investment

Aldatu Biosciences

Using our novel platform technology — Pan Degenerate Amplification and Adaptation, or  PANDAA™ — Aldatu is able to take an already low-cost and sensitive diagnostic, known as qPCR, and enable it for HIV drug resistance genotyping. For the first time, PANDAA™ HIV genotyping empowers healthcare providers with a solution to properly match HIV patients with effective drugs, thus improving patient outcomes and reducing the per-patient cost of HIV care. Learn more.